SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-23-069193
Filing Date
2023-12-11
Accepted
2023-12-11 07:03:35
Documents
14
Period of Report
2023-12-11
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K lxeo-20231211.htm   iXBRL 8-K 40558
2 EX-99.1 lxeo-ex99_1.htm EX-99.1 143987
3 GRAPHIC img46940271_0.jpg GRAPHIC 281352
  Complete submission text file 0000950170-23-069193.txt   701832

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT lxeo-20231211_lab.xml EX-101.LAB 14010
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT lxeo-20231211_pre.xml EX-101.PRE 10285
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT lxeo-20231211.xsd EX-101.SCH 2466
8 EXTRACTED XBRL INSTANCE DOCUMENT lxeo-20231211_htm.xml XML 4931
Mailing Address 345 PARK AVENUE SOUTH FLOOR 6 NEW YORK NY 10010
Business Address 345 PARK AVENUE SOUTH FLOOR 6 NEW YORK NY 10010 (212) 547-9879
Lexeo Therapeutics, Inc. (Filer) CIK: 0001907108 (see all company filings)

IRS No.: 854012572 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41855 | Film No.: 231476898
SIC: 2836 Biological Products, (No Diagnostic Substances)